Status:
UNKNOWN
Convalescent Plasma for COVID-19
Lead Sponsor:
Enos Bernasconi
Conditions:
Blood Plasma Therapy
COVID
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to patients with moderate to severe COVID-19 and assess: * the titer of anti-COVID-19 antibodies in the donors an...
Eligibility Criteria
Inclusion
- Hospitalized adult patients 18 - 75 y.o. with confirmed COVID-19 infection by nasopharyngeal swab;
- radiologically confirmed pneumonia;
- SpO2 \> 92o/o and \< 96% (room air);
- ongoing thromboembolic prophylaxis.
Exclusion
- Participation to another COVID-19 trial;
- severe COVID-19 disease (SpO2 \< 93o/o in room air);
- severe allergic transfusion reactions or anaphylaxis in the patient history;
- documented lgA deficiency;
- unstable heart disease with signs of circulatory overload;
- malignancies or other concomitant diseases with poor short-term prognosis;
- pregnancy.
Key Trial Info
Start Date :
July 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04365439
Start Date
July 20 2020
End Date
June 30 2021
Last Update
March 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale Regionale Locarno
Locarno, Canton Ticino, Switzerland, CH-6600